Columbia Laboratories Buys Molecular Profiles for $25M

Pharmaceutical Business Review is reporting that Columbia Laboratories (NASDAQ:CBRX) has acquired Molecular Profiles, a UK-based provider of pharmaceutical formulation development and manufacturing services, for about $25 million.

As quoted in the market news: 

The deal includes $16.7m in cash and 1,051,323 shares of Columbia common stock, which are subject to a 12-month lock-up period, representing ten to eleven times Molecular Profiles’ expected EBITDA for its fiscal year ending 31 July 2014.

Additionally, the company expects to realize a double-digit impact to its EBITDA and operational synergies of about $400,000 per year.

Click here for the full story in Pharmaceutical Business Review